MONJUVI IS A MONOCLONAL ANTIBODY THAT TARGETS CD19 ANTIGENS1

  • MONJUVI (tafasitamab-cxix) is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and in several B-cell malignancies, including DLBCL

Mechanism of action of MONJUVI1
3-pronged mechanism of action graphic illustrating how MONJUVI + lenalidomide works in the body
  • Upon binding to CD19, tafasitamab-cxix mediates B-cell lysis through:

  1. Apoptosis

    Immune-effector mechanisms, including

  2. Antibody-dependent cellular cytotoxicity (ADCC)
  3. Antibody-dependent cellular phagocytosis (ADCP)
  • In studies conducted in vitro in DLBCL tumor cells, tafasitamab-cxix, in combination with lenalidomide, resulted in increased ADCC activity compared to tafasitamab-cxix or lenalidomide alone


MOA=mechanism of action; Fc=fragment crystallizable; DLBCL=diffuse large B-cell lymphoma.